OpenURL Connection Search

Select item for more details and to access through your institution.

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.
Published in:
Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 10, p. 2581, doi. 10.1007/s00432-021-03780-7
By:
- Schriegel, Felix;
- Taschner-Mandl, Sabine;
- Bernkopf, Marie;
- Grunwald, Uwe;
- Siebert, Nikolai;
- Ambros, Peter F.;
- Ambros, Inge;
- Lode, Holger N.;
- Henze, Guenter;
- Ehlert, Karoline
Publication type:
Article
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18.
Published in:
Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.839783
By:
- Glienke, Wolfgang;
- Dragon, Anna Christina;
- Zimmermann, Katharina;
- Martyniszyn-Eiben, Alexandra;
- Mertens, Mira;
- Abken, Hinrich;
- Rossig, Claudia;
- Altvater, Bianca;
- Aleksandrova, Krasimira;
- Arseniev, Lubomir;
- Kloth, Christina;
- Stamopoulou, Andriana;
- Moritz, Thomas;
- Lode, Holger N.;
- Siebert, Nikolai;
- Blasczyk, Rainer;
- Goudeva, Lilia;
- Schambach, Axel;
- Köhl, Ulrike;
- Eiz-Vesper, Britta
Publication type:
Article
Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody.
Published in:
PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107692
By:
- Siebert, Nikolai;
- Seidel, Diana;
- Eger, Christin;
- Jüttner, Madlen;
- Lode, Holger N.
Publication type:
Article
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Published in:
Cancer Immunology, Immunotherapy, 2015, v. 64, n. 5, p. 621, doi. 10.1007/s00262-015-1669-5
By:
- Seidel, Diana;
- Shibina, Anastasia;
- Siebert, Nikolai;
- Wels, Winfried;
- Reynolds, C.;
- Huebener, Nicole;
- Lode, Holger
Publication type:
Article
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.
Published in:
Cancer Immunology, Immunotherapy, 2013, v. 62, n. 6, p. 999, doi. 10.1007/s00262-013-1413-y
By:
- Lode, Holger;
- Schmidt, Manuela;
- Seidel, Diana;
- Huebener, Nicole;
- Brackrock, Diana;
- Bleeke, Matthias;
- Reker, Daniel;
- Brandt, Sven;
- Mueller, Hans-Peter;
- Helm, Christiane;
- Siebert, Nikolai
Publication type:
Article
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.
Published in:
Cancers, 2023, v. 15, n. 13, p. 3364, doi. 10.3390/cancers15133364
By:
- Lode, Holger N.;
- Ladenstein, Ruth;
- Troschke-Meurer, Sascha;
- Struppe, Linda;
- Siebert, Nikolai;
- Zumpe, Maxi;
- Ehlert, Karoline;
- Huber, Stefanie;
- Glogova, Evgenia;
- Hundsdoerfer, Patrick;
- Eggert, Angelika;
- Zaniewska-Tekieli, Anna;
- Balwierz, Walentyna;
- Wieczorek, Aleksandra
Publication type:
Article
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
Published in:
Cancers, 2023, v. 15, n. 13, p. 3317, doi. 10.3390/cancers15133317
By:
- Siebert, Nikolai;
- Zumpe, Maxi;
- Schwencke, Christian Heinrich;
- Biskupski, Simon;
- Troschke-Meurer, Sascha;
- Leopold, Justus;
- Zikoridse, Alexander;
- Lode, Holger N.
Publication type:
Article
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.
Published in:
Cancers, 2023, v. 15, n. 3, p. 904, doi. 10.3390/cancers15030904
By:
- Troschke-Meurer, Sascha;
- Zumpe, Maxi;
- Meißner, Lena;
- Siebert, Nikolai;
- Grabarczyk, Piotr;
- Forkel, Hannes;
- Maletzki, Claudia;
- Bekeschus, Sander;
- Lode, Holger N.
Publication type:
Article
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
Published in:
Cancers, 2022, v. 14, n. 23, p. 5802, doi. 10.3390/cancers14235802
By:
- Klingel, Leah;
- Siebert, Nikolai;
- Troschke-Meurer, Sascha;
- Zumpe, Maxi;
- Ehlert, Karoline;
- Huber, Stefanie;
- Loibner, Hans;
- Mutschlechner, Oliver;
- Lode, Holger N.
Publication type:
Article
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.
Published in:
Cancers, 2022, v. 14, n. 23, p. 5751, doi. 10.3390/cancers14235751
By:
- Marx, Sascha;
- Wilken, Fabian;
- Miebach, Lea;
- Ispirjan, Mikael;
- Kinnen, Frederik;
- Paul, Sebastian;
- Bien-Möller, Sandra;
- Freund, Eric;
- Baldauf, Jörg;
- Fleck, Steffen;
- Siebert, Nikolai;
- Lode, Holger;
- Stahl, Andreas;
- Rauch, Bernhard H.;
- Singer, Stephan;
- Ritter, Christoph;
- Schroeder, Henry W. S.;
- Bekeschus, Sander
Publication type:
Article
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta.
Published in:
Cancers, 2022, v. 14, n. 19, p. 4842, doi. 10.3390/cancers14194842
By:
- Siebert, Nikolai;
- Leopold, Justus;
- Zumpe, Maxi;
- Troschke-Meurer, Sascha;
- Biskupski, Simon;
- Zikoridse, Alexander;
- Lode, Holger N.
Publication type:
Article
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Published in:
Cancers, 2018, v. 10, n. 10, p. 387, doi. 10.3390/cancers10100387
By:
- Siebert, Nikolai;
- Troschke-Meurer, Sascha;
- Marx, Madlen;
- Zumpe, Maxi;
- Ehlert, Karoline;
- Gray, Juliet;
- Garaventa, Alberto;
- Manzitti, Carla;
- Ash, Shifra;
- Klingebiel, Thomas;
- Beck, James;
- Castel, Victoria;
- Valteau-Couanet, Dominique;
- Loibner, Hans;
- Ladenstein, Ruth;
- Lode, Holger N.
Publication type:
Article
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Published in:
Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.690467
By:
- Seitz, Christian Martin;
- Flaadt, Tim;
- Mezger, Markus;
- Lang, Anne-Marie;
- Michaelis, Sebastian;
- Katz, Marie;
- Syring, Desireé;
- Joechner, Alexander;
- Rabsteyn, Armin;
- Siebert, Nikolai;
- Troschke-Meurer, Sascha;
- Zumpe, Maxi;
- Lode, Holger N.;
- Yang, Sile F.;
- Atar, Daniel;
- Mast, Anna-Sophia;
- Scheuermann, Sophia;
- Heubach, Florian;
- Handgretinger, Rupert;
- Lang, Peter
Publication type:
Article
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
Published in:
PLoS ONE, 2016, v. 11, n. 3, p. 1, doi. 10.1371/journal.pone.0150479
By:
- Eger, Christin;
- Siebert, Nikolai;
- Seidel, Diana;
- Zumpe, Maxi;
- Jüttner, Madlen;
- Brandt, Sven;
- Müller, Hans-Peter;
- Lode, Holger N.
Publication type:
Article
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Published in:
British Journal of Cancer, 2023, v. 129, n. 11, p. 1780, doi. 10.1038/s41416-023-02457-x
By:
- Lode, Holger N.;
- Ehlert, Karoline;
- Huber, Stephanie;
- Troschke-Meurer, Sascha;
- Siebert, Nikolai;
- Zumpe, Maxi;
- Loibner, Hans;
- Ladenstein, Ruth
Publication type:
Article
Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.
Published in:
2018
By:
- Ceylan, Kiraz;
- Jahns, Luciana J.;
- Lode, Bjoern N.;
- Ehlert, Karoline;
- Kietz, Silke;
- Troschke‐Meurer, Sascha;
- Siebert, Nikolai;
- Lode, Holger N.;
- Troschke-Meurer, Sascha
Publication type:
journal article
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
Published in:
Journal of Neuro-Oncology, 2020, v. 147, n. 3, p. 577, doi. 10.1007/s11060-020-03470-3
By:
- Marx, Sascha;
- Wilken, Fabian;
- Wagner, Isabel;
- Marx, Madlen;
- Troschke-Meurer, Sascha;
- Zumpe, Maxi;
- Bien-Moeller, Sandra;
- Weidemeier, Martin;
- Baldauf, Joerg;
- Fleck, Steffen K.;
- Rauch, Bernhard H.;
- Schroeder, Henry W. S.;
- Lode, Holger;
- Siebert, Nikolai
Publication type:
Article
Hepatocellular apoptosis is mediated by TNFα-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure.
Published in:
Apoptosis, 2008, v. 13, n. 12, p. 1427, doi. 10.1007/s10495-008-0269-7
By:
- Kuhla, Angela;
- Eipel, Christian;
- Siebert, Nikolai;
- Abshagen, Kerstin;
- Menger, Michael;
- Vollmar, Brigitte
Publication type:
Article
Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.
Published in:
PLoS ONE, 2018, v. 13, n. 11, p. 1, doi. 10.1371/journal.pone.0207320
By:
- Marx, Madlen;
- Zumpe, Maxi;
- Troschke-Meurer, Sascha;
- Shah, Diana;
- Lode, Holger N.;
- Siebert, Nikolai
Publication type:
Article

Found: 19

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD<sub>2</sub> and Releasing Inducible IL-18.

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD<sub>2</sub> Antibody.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD-specific anti-neuroblastoma immune response.

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy.

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models.

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta.

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.

Generation and Characterization of a Human/Mouse Chimeric GD<sub>2</sub>-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.

Inflammatory response and treatment tolerance of long-term infusion of the anti-GD<sub>2</sub> antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.

Hepatocellular apoptosis is mediated by TNFα-dependent Fas/FasLigand cytotoxicity in a murine model of acute liver failure.

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.